论文部分内容阅读
目的:探讨健脾补肾方对乳腺癌术后TEC方案化疗不良反应的影响,为健脾补肾方能更好的应用于临床提供依据。方法:依据标准,共收集60例,随机分为治疗组(健脾补肾方联合化疗组)和对照组(单纯西医化疗组),每组各30例。比较两组患者的心电图、心肌肌钙蛋白I、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、中医证候积分、卡氏评分。结果:1)两组患者化疗后心电图、CK、CK-MB异常率比较发现,第一周期化疗前后及第二周期化疗前比较均无明显差异,无统计学意义。在第二周期化疗后心电图、CK、CK-MB异常率比较,差异有统计学意义。说明健脾补肾方可降低第二周期化疗后心电图、CK、CK-MB异常率。2)化疗后治疗组中医证候积分有效率86.67%,高于对照组有效率53.33%,差异有显著统计学意义;治疗组卡式评分有效率93.33%,高于对照组有效率53.33%,治疗组高于对照组,差异有显著统计学意义。结论:健脾补肾方应用于脾肾两虚证乳腺癌患者术后化疗后,能减轻心脏毒副反应,并提高患者的生活质量。
Objective: To investigate the effect of Jianpi Bushen Recipe on chemotherapy regimens of postoperative TEC regimen in patients with breast cancer, and to provide basis for better application of Jianpi Bushen recipe in clinic. Methods: According to the standard, a total of 60 cases were collected and randomly divided into treatment group (Jianpi Bushen Recipe combined with chemotherapy group) and control group (Western medicine chemotherapy group), 30 cases in each group. The electrocardiogram, cardiac troponin I, creatine kinase (CK), creatine kinase isoenzyme (CK-MB), TCM syndrome score and Karnofsky score were compared between the two groups. Results: 1) Comparison of electrocardiogram, CK, CK-MB abnormalities after chemotherapy between the two groups found no significant difference before and after the first cycle chemotherapy and before the second cycle chemotherapy, no statistical significance. ECG in the second cycle after chemotherapy, CK, CK-MB abnormalities, the difference was statistically significant. Description of spleen and kidney can reduce the second cycle of chemotherapy after electrocardiogram, CK, CK-MB abnormalities. 2) After treatment, the effective rate of TCM syndromes in the treatment group was 86.67%, which was 53.33% higher than that in the control group, the difference was statistically significant. The effective rate of the treatment group was 93.33%, higher than that of the control group 53.33% The treatment group than the control group, the difference was statistically significant. Conclusion: Spleen-invigorating and Kidney-invigorating recipe applied to postoperative chemotherapy in patients with spleen and kidney deficiency syndrome can reduce cardiac toxicity and improve the quality of life of patients.